Pfizer 3Q Revenues: $13.2 billion (-42%) 3Q Loss: $2.4 billion (earnings were $8.6 billion 3Q22) YTD Revenues: $44.2 billion (-42%) YTD Earnings: $5.5 billion (-79%) Comments: Decline in revenues due to a drop in Paxlovid and Comirnaty sales globally, down 97% to $7.3 billion, and 70% to $3.1 billion, respectively. Abrysvo RSV vaccine revenues in the U.S. were $375 million following FDA approval of the older adult indication in May 2023. Migraine drug Nurtec ODT/Vydura and sickle cell disea...